Cover Image
市場調查報告書

肉毒桿菌的全球市場

Botulinum Toxin

出版商 Global Industry Analysts, Inc. 商品編碼 236787
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肉毒桿菌的全球市場 Botulinum Toxin
出版日期: 2018年01月01日 內容資訊: 英文 190 Pages
簡介

本報告提供全球肉毒桿菌市場相關調查,彙整市場概要與成長趨勢,產品概要,及加入此市場的主要企業的簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 肉毒桿菌:美容和治療的用途擴大推動成長
    • 治療用肉毒桿菌用途
    • 已開發地區主導市場
    • 發展中國家推動未來的成長
    • 醫療費高等促進治療用肉毒桿菌的需求
    • 美容的肉毒桿菌:有前途的用途市場
    • 帶動美容用肉毒桿菌市場的因素
    • 肌肉骨骼適應數的增加
    • 製藥公司關注有利可圖的BT市場
  • 競爭環境
    • 肉毒桿菌毒素市場競爭激烈
    • Allergan領導全球BTX市場
    • 肉毒桿菌產品
    • 肉毒桿菌:領導品牌
    • 生物相似藥
    • 已經過核准產品缺乏差異化
    • 主要的神經毒素比較
    • 主要的肉毒桿菌產品的檢討 其他
  • 市場趨勢與課題
    • 非侵入性美容治療的需求增加
    • 臉部注射劑市場上偏好的解決方案
    • 肉毒桿菌的人氣
    • 壽命的延長和可支配所得的增加 其他
  • 產品概要
    • 能治療的毒素
    • 結構·作用機制
    • 弱點
    • 分類
    • 手術
    • 美容的應用
    • 治療的應用
    • 副作用
  • 產品引進/認證
  • 近幾年的產業活動
  • 主要企業
    • Allergan Plc
    • Daewoong Pharmaceutical Co., Ltd.
    • HUGEL Pharma
    • Ipsen Group
    • Medy-Tox Inc.
    • Merz Pharma GmbH & Co. KGaA
    • Metabiologics, Inc.
    • Revance Therapeutics, Inc.
    • US WorldMed
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1833

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 14 companies including many key and niche players such as -

Allergan Plc
Daewoong Pharmaceutical Co., Ltd.
HUGEL Pharma
Ipsen Group
Medy-Tox Inc.
Merz Pharma GmbH & Co. KGaA

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

  • Cosmetic Applications
  • Therapeutic Applications

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth
  • Therapeutic BTX Applications Lead, Cosmetic BTX Gradually Gaining Momentum
    • Table 1: Global Therapeutic BTX Neurotoxin Market (2016): Percentage Breakdown of Value Sales by Therapeutic Indication (includes corresponding Graph/Chart)
  • Developed Regions Dominate Botulinum Toxin Market
  • Developing Markets to Drive Future Growth
  • Increase in Healthcare Spending Stirs Demand for BTX in Therapeutic Applications
    • Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)
    • Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)
  • Cosmetic BTX - A Promising Application Market
  • Factors Propelling the Cosmetic BT Market - In a Nut Shell
  • Rise in the Number of Musculoskeletal Indications - Potential for Growth
  • Pharma Companies Keenly Eye Lucrative BT Market

2. COMPETITIVE LANDSCAPE

  • Intense Competition Characterizes Botulinum Toxin Market
  • Allergan Leads the Global BTX Market
    • Table 4: Leading Products in the Global Aesthetic Botulinum Toxin Market (2016): Percentage Breakdown of Value Sales for Botox, Dysport, Dysport/Azzalure, Meditoxin, and Xeomin (includes corresponding Graph/Chart)
  • Botulinum Toxin Products Worldwide
  • Botox - The Leading Brand in Cosmetic BTX Market
  • Biosimilar BTX Variants Challenge Botox's Leadership
  • Lack of Differentiation among Approved BTX Products
  • Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and Efficacy
  • Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario
  • A Review of Major BTX Products
  • Comparison of Botox(r), Dysport(r) and Xeomin(r) by Indications and Year of Approval
  • BOTOX(r)
    • Approvals and Indications of Botox in Select Regions
    • Key Characteristics of Botox(r) and Botox(r) Cosmetic
    • Common Adverse Reactions with Botox
    • Therapeutics to Offer Higher Prospects for Botox
      • Botox Therapeutic Approvals in the US by Indication
    • Migraine Indication Bolsters Allergan's Botox Sales
  • Dysport(r)
    • Key Characteristics of Dysport(r)
    • Ipsen Counts on New Indications for Future Growth of Dysport
      • Dysport Therapeutic Development Pipeline by Region
  • Xeomin(r)
    • Key Characteristics of Xeomin(r)
    • Xeomin(r) FDA Approval and Indications
    • Global Expansion Helps Merz Gain in the BTX Market
  • Myobloc(r)/NeuroBloc(r)
    • Key Characteristics of Myobloc(r)
  • Meditoxin(r)
  • RT002
  • Other Products

3. MARKET TRENDS & ISSUES

  • Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market
    • Table 5: Non-Surgical Cosmetic Procedures Worldwide (2016): Percentage Breakdown of Procedure Volume for Injectables (Botulinum Toxin, Calcium Hydroxylapatite, Hyaluronic Acid and Poly-L-Lactic Acid), Facial Rejuvenation and Others (includes corresponding Graph/Chart)
  • Botulinum Toxin - The Preferred Solution in Facial Injectables Market
    • Table 6: Global Dermal Fillers Market by Application (2017): Percentage Breakdown of Value Sales for Face Lift Treatment, Facial Line Correction Treatment, Lip Treatment and Others (includes corresponding Graph/Chart)
    • Table 7: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2016): Percentage Breakdown of Procedure Volume by Gender (includes corresponding Graph/Chart)
    • Table 8: Number of Cosmetic Botulinum Toxin Procedures (in '000s) in Select Countries for the Year 2016 (includes corresponding Graph/Chart)
  • Botox Gains Popularity among Millennials
    • Table 9: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2016): Percentage Breakdown of Procedure Volume by Age Group (includes corresponding Graph/Chart)
  • Longer Life Expectancy and Rising Disposable Incomes Propel Sales of Cosmetic BTX
    • Table 10: Life Expectancy at Birth in Years of People in Select Countries (2017) (includes corresponding Graph/Chart)
    • Table 11: Life Expectancy at Birth (in Years) of Men and Women by Region (2017) (includes corresponding Graph/Chart)
  • BTX - The Wonder Drug for Increasing Number of Non-Cosmetic Uses
  • BoNT/X - The New Toxin with Potential Use in New Therapeutic Areas
  • Topical Botulinum Toxin: Needle-Free Administration Imparts an Edge over Injected Variants
  • Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
  • Urgent Need for Physician Education about Off-Label Usage
  • Campaigns Boost Patient Awareness
  • Digital Revolution to Impact Consumer Choices
  • Financing of Non-Reimbursed Healthcare: Need of the Hour
  • Combination Therapies: A Double Whammy Success
  • Botulinum Toxin - Potential Applications in Treatment of Dental Diseases
  • Short-lived Aesthetic Effects: A Strong Business Case for Revision Treatments
  • Novel Injection Systems for Highly Precise Dosage of Botulinum Toxin
  • Undesirable Side Effects: A Challenge to Reckon With
  • Immunogenicity Undermines Patient Compliance
    • Reduction of Protein Load in BTX Products - The Probable Answer for Immunogenicity
  • Antigenicity: A Problematic Issue in Drug Development
  • Stringent Regulations Delay Market Approvals & Put Reimbursements in Limbo
  • Study Offers Support for Possible Remote Effects with Botulinum Toxin
  • Higher Product Costs to Challenge Market Growth
  • Consumer Skepticism: The Biggest Challenge to Beat
  • Animal Cruelty - A Part & Parcel of Botox Testing
  • Botulinum Toxins - A Wonder Drug or Bio-terror Threat?
  • Fears of Terrorism & Biological Warfare Thwart International Trade

4. PRODUCT OVERVIEW

  • Botulinum Toxin: A Poison That Cures
  • Structure & Mechanism of Action
  • Disadvantages
  • Classification of Botulinum Toxin
  • Botulinum Toxin Type A
    • Historical Timeline of Botulinum Toxin: 1885-2002
  • Botulinum Toxin Type B
  • Procedure
  • Anaesthesia
  • Injection Procedure
  • Applications of Botulinum Toxin
  • Cosmetic Applications
    • Glabellar Lines
    • Facial Wrinkles
    • Key Cosmetic Indications for Botulinum Toxin
    • Crow's Feet
    • Forehead Rhytids
    • Temporal Brow Lift
    • Lower Eyelid Rhytids
    • Downturned Lips
    • Pebbly Chin
  • Therapeutic Applications
    • Movement Disorders/Pain
      • Cervical Dystonia
      • Hemifacial Spasm
      • Blepharospasm
      • Strabismus
      • Site of Injection and Doses of Neurotoxins used in the Treatment of Dystonias
      • Chronic Pain
      • Botox in Migraine Treatment
      • List of Countries where Botox has been Approved for Prophylaxis of Headache in Adults Suffering from Chronic Migraine
    • Table 12: Modes of Injection of Onabotulinum ToxinA for Chronic Migraine by Dose and Muscle Injected (includes corresponding Graph/Chart)
      • Hyperhidrosis
      • Bladder Dysfunctions
      • Spasticity
      • Other Applications
  • Side Effects

5. PRODUCT INTRODUCTIONS/APPROVALS

  • Ipsen Gains FDA Approval for Dysport(r) in Treatment of Lower Limb Spasticity Treatment in Adults
  • Medytox to Introduce Coretox Protein Free Botox Product
  • Allergan's BOTOX(r) Cosmetic Wins FDA Approval for Third Indication
  • Ipsen Gains FDA Approval for Dysport(r) in Treatment of Pediatric Lower Limb Spasticity
  • Merz Receives European Approval for Bocouture(r) Use in Treatment of Upper Facial Lines
  • Merz Announces Availability of Xeomin(r) 200-unit Single-Dose Vial in US
  • FDA Approves BOTOX(r) for Treatment of Adult Lower Limb Spasticity

6. RECENT INDUSTRY ACTIVITY

  • Allergan's VISTABEL(r) Receives Positive Opinion for Severe Forehead Lines Treatment in Adults
  • Merz and Teijin Partner to Commercialize Xeomin(r) in Japan
  • Ipsen Inks Promotion Agreement with Saol Therapeutics
  • Bain Capital Takes Over Hugel
  • Huons to Invest in New BTX Plant in Korea
  • Allergan Gains Marketing Approval for BOTOX Vista(r) in Japan
  • Allergan Takes Over Anterios
  • Daewoong Pharm Expands Sales of Nabota BTX Biosimilar to Southeast Asia
  • Revance Acquires BTX-related IP from Botulinum Toxin Research Associates
  • Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug Candidate
  • Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins
  • Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel
  • Revance Commences Phase 2 Study for RT002 Botulinum Toxin Type A
  • Revance Begins Phase 2 Trial for Botulinum toxin Type A Topical Gel
  • Bloomage BioTechnology and Medytox to Establish JV in China
  • Ipsen Gains FDA's sBLA Approval for Dysport(r)
  • Actavis Bags FDA Approval for Expanding BOTOX(r) Label
  • Actavis Acquires Allergan

7. FOCUS ON SELECT PLAYERS

  • Allergan Plc (Ireland)
  • Daewoong Pharmaceutical Co., Ltd. (South Korea)
  • HUGEL Pharma (South Korea)
  • Ipsen Group (France)
  • Medy-Tox Inc. (South Korea)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Metabiologics, Inc. (USA)
  • Revance Therapeutics, Inc. (USA)
  • US WorldMeds (USA)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 15: World 14-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 21: World 14-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Therapeutic BTX Market - New Entrants Slow in Gaining Market Share
      • Approved Therapeutic Indications of Botulinum Toxin in the US by Year of Approval
      • Neurogenic OAB - A Relatively Smaller Market Opportunity
      • Idiopathic OAB Bodes Healthy Prospects for Botox
    • Cosmetic BTX Market: Rapid Growth in Store
    • Table 22: Age-wise Distribution for Botulinum Toxin Procedures Performed in the US for the Year 2016 (includes corresponding Graph/Chart)
    • Table 23: Gender Distribution for Botulinum Toxin Procedures Performed in the US (2016) (includes corresponding Graph/Chart)
      • Increasing Demand for Cosmetic Treatments Bodes Well for BTX Market
      • Some Interesting Facts on Cosmetic Procedures
    • Table 24: Number of Surgical & Non-Surgical Cosmetic Procedures ('000s) in the US for the Years 1997, 2015 & 2016 (includes corresponding Graph/Chart)
    • Table 25: Top 5 Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (In '000s) for 2016 (includes corresponding Graph/Chart)
    • Table 26: Top 5 Non-Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed ('000s) for 2016 (includes corresponding Graph/Chart)
    • Table 27: Total Number of Cosmetic Procedures Performed by Category in the US (2016) (includes corresponding Graph/Chart)
    • Table 28: Number of Botulinum Toxin Procedures Performed in the US (1997, 2015 and 2016) (includes corresponding Graph/Chart)
      • Demand for Professional Help On Rise
      • Aging Baby Boomers Drive Aesthetic Business
    • Table 29: US Population by Age Group (2017): Percentage Breakdown for 0-14, 15-24, 25-59 and 65+ Age Groups (includes corresponding Graph/Chart)
    • Table 30: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
      • Expanding Physician Base Extends Impetus to Growth
    • Table 31: Average Physician/Surgeon Fees for Botulinum Toxin Per Procedure in the US (2007- 2016) (includes corresponding Graph/Chart)
    • Competitive Landscape
      • Allergan's Botox Leads Cosmetic BTX Market
      • Major BTX Products and Associated Fillers in the Cosmetic Botulinum Toxin Market
    • Table 32: Leading Brands in the US Cosmetic Neurotoxin Treatment Market (2016): Percentage Breakdown of Value Sales for Botox, Dysport and Others (includes corresponding Graph/Chart)
      • Dysport Takes on Botox in the Therapeutic Space
    • Table 33: Leading Brands in the US Therapeutic Botulinum Toxin Market (2016): Percentage Breakdown of Value Sales for Botox and Dysport (includes corresponding Graph/Chart)
    • AAN Releases New Guidelines on BTX for Identified Disorders
    • Rise in Botulinum Toxin Lawsuits - A Concern for Physicians?
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 34: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 35: US Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 36: US 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 37: Canadian Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 38: Canadian Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 39: Canadian 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Table 40: Non-Surgical Aesthetic Procedures in Japan (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 41: Japanese Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 42: Japanese Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 43: Japanese 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • BTX Cosmetic Market Positioned for Growth
      • Botox Approvals and Indications in Select European Countries
    • Table 44: Non-Surgical Aesthetic Procedures in Select European Countries (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart)
      • Anti-Aging Treatment on the Rise among Young Mothers
    • Regulations for Botulinum Toxin Usage in the EU
    • The United Kingdom
      • Cosmetic Treatment Procedures in the UK
      • Snapshots
    • Russia
      • Mandates Registration of BTX Drugs
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 45: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 46: European Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 47: European 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
      • Botox Approvals and Indications in Select Asian Countries
    • A PEEK INTO SELECT MARKETS
      • Australia
    • Table 48: Non-Surgical Aesthetic Procedures in Australia (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart)
      • China
      • Rising Demand for Cosmetic Treatments - Opportunity for BTX
      • Botulinum Toxin Injections Approved by China Food and Drug Administration (CFDA)
      • India
    • Table 49: Non-Surgical Aesthetic Procedures in India (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart)
      • South Korea
      • Botulinum Toxin Market - An Overview
    • Table 50: South Korean Botulinum Toxin Use by Application for the Years 2005, 2010 and 2015 (includes corresponding Graph/Chart)
      • Strong Demand for Cosmetic Procedures - Potential for BTX Market
    • Table 51: Working Women as % of Total Female Population for 2005, 2010, 2015 & 2016 (includes corresponding Graph/Chart)
    • Table 52: Aging Population in Korea (2015 & 2025): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)
    • Table 53: Foreign Patients Visiting Korea for Plastic Surgery & Dermatology Procedures as a % of Total Visits of Foreign Patients (includes corresponding Graph/Chart)
      • Meditoxin Dominates Domestic BTX Market
    • Table 54: Leading Players in the South Korean Botulinum Toxin Market (2016): Percentage Breakdown of Sales for Daewoong Pharma, Hugel, Medytox and Others (includes corresponding Graph/Chart)
      • List of Domestic Botox Products in Korea
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 55: Asia-Pacific Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 56: Asia-Pacific Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 57: Asia-Pacific 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Latin America: Facial Injectables Market Set for Strong Growth
    • Table 58: Non-Surgical Aesthetic Procedures in Brazil (2016): Percentage Breakdown of Number of Procedures by Procedure Type (includes corresponding Graph/Chart)
    • Israel: Health Ministry Bans Cosmetic Botox Treatment by Dentists
    • Botox Approvals and Indications in RoW
      • Botox Approvals and Indications in Select Latin American Regions
      • Botox Approvals and Indications in Other Select Global Regions
  • B. Market Analytics
    • Table 59: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 60: Rest of World Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Thousand for the Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 61: Rest of World 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Back to Top